JPMorgan Chase & Co. lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 143.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,358,507 shares of the medical device company’s stock after acquiring an additional 7,738,678 shares during the quarter. JPMorgan Chase & Co. owned 2.71% of DexCom worth $107,170,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Advisor Group Inc. increased its holdings in DexCom by 104.9% in the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after buying an additional 837 shares during the last quarter. IFP Advisors Inc increased its holdings in DexCom by 30.5% in the second quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after buying an additional 568 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in DexCom by 9.2% in the second quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock valued at $216,000 after buying an additional 250 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in DexCom by 12.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after buying an additional 354 shares during the last quarter. Finally, Balyasny Asset Management LLC bought a new stake in DexCom in the second quarter valued at about $249,000.

In related news, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $69.34, for a total transaction of $416,040.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Andrew K. Balo sold 3,244 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $72.27, for a total value of $234,443.88. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,954 shares of company stock valued at $2,266,296. Insiders own 1.70% of the company’s stock.

Several analysts recently weighed in on DXCM shares. TheStreet lowered DexCom from a “c-” rating to a “d+” rating in a report on Wednesday, October 25th. ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Wedbush reissued a “buy” rating and issued a $76.00 price objective on shares of DexCom in a report on Wednesday, October 4th. Robert W. Baird reissued a “hold” rating and issued a $79.00 price objective on shares of DexCom in a report on Sunday, September 10th. Finally, Barclays started coverage on DexCom in a report on Friday, September 15th. They issued an “equal weight” rating and a $76.00 price objective for the company. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $70.69.

DexCom, Inc. (DXCM) opened at $58.02 on Monday. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84. DexCom, Inc. has a 52-week low of $42.62 and a 52-week high of $88.80.

TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/12/04/jpmorgan-chase-co-has-107-17-million-stake-in-dexcom-inc-dxcm.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.